<DOC>
	<DOCNO>NCT00517062</DOCNO>
	<brief_summary>Study hypothesis : Growth hormone ( GH ) , generation free 'bioavailable ' insulin-like growth factor ( IGF ) -I , improve insulin sensitivity adult GH deficiency . Study aim : The purpose study determine mechanism low dose GH treatment affect body 's sensitivity insulin action whether low GH dose affect body 's handle steroid hormone level ( cortisol clearance ) adult GH deficiency . Study design : Men woman confirm GH deficiency , recently GH treatment invite participate study . The subject assess initial visit ascertain suitability participate study . If suitable , equal number men woman randomize receive either low dose GH placebo injection 3 month . Before , treatment , subject assess regularly blood test , scan fat biopsy . At first final visit , test include scan measure amount whole body fat fat stomach area , muscle , liver ; blood test measure level cortisol , fat tissue ( take biopsy ) analysis measure density IGF-I muscle ; whereas blood test examine insulin sensitivity also collect . This study use Genotropin Genotropin pen device , data analyze use computer statistical program identity subject cod maintain confidentiality .</brief_summary>
	<brief_title>Low Dose Growth Hormone ( GH ) Insulin Sensitivity Cortisol Production Rates</brief_title>
	<detailed_description>The study double-blinded . One hundred subject screen eligibility initially , 24 subject enrol 12 subject randomize receive low GH dose ( 0.1 mg/day ) treatment 12 subject receive Placebo treatment 3 month , allow 10 % drop-out rate . The subject teach either Endocrine Nurse Specialists self-administer GH subcutaneous injection use Genotropin pen device . Visit 1 , Initial Screening Assessment ( out-patient ) - Physical examination , weight , height , waist circumference measurement - Fasting blood glucose level Visit 2 , Baseline Assessment ( in-patient ) - Physical examination , weight , height , waist circumference measurement - Fasting blood test glucose , insulin , C-peptide , free IGF-I , total IGF-I , IGF-2 , IGFBPs -1 -3 , non-esterified fatty acid lipid profile - MRS , abdominal CT DEXA scan - One-step 3-hour hyperinsulinaemic euglycaemic clamp - Cortisol production rate urine cortisol collection - Fat biopsy take end assessment cortisol production rate Visit 3 , Interim Assessment ( Month 1 ) ( out-patient ) - Documentation adverse effect - Fasting blood test glucose , insulin , C-peptide , free IGF-I , total IGF-I , IGF-2 , IGFBPs -1 -3 Visit 4 , Final Assessment ( Month 3 ) ( in-patient ) - Physical examination , weight , height , waist circumference measurement - Fasting blood test glucose , insulin , C-peptide , free IGF-I , total IGF-I , IGF-2 , IGFBPs -1 -3 , non-esterified fatty acid lipid profile - MRS , abdominal CT DEXA scan - One-step 3-hour hyperinsulinaemic euglycaemic clamp - Cortisol production rate urine cortisol collection - Fat biopsy take end assessment cortisol production rate Any extra blood remain sample blood drawn may bank indefinitely confidential identifier , may give researcher future examine potential cause diabetes heart diseases adult . These blood sample , however , use genetic study .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Age range 18 75 year BMI exceed 40 kg/m2 Confirmed GH deficient least one provocative test , e.g . insulin tolerance test and/ GHRH/arginine Not receive GH therapy within last 6 month On stable standardized hydrocortisone replacement dose regimen ( twice day 8 AM 4 PM ) , If pituitary hormone deficiency present , patient must optimal pituitary hormone replacement therapy , e.g . Thyroxine , testosterone oestrogen replacement Normal renal hepatic function Prepared selfinject Untreated subclinically hypo/hyperthyroid Untreated subclinically treated hypocortisolism Type 1 2 diabetes mellitus Subjects evidence nephropathy cause Subjects evidence retinopathy cause Any medical illness may affect interpretation result Pregnant Emotional/social instability likely prejudice study completion Previous history know malignancy Recurrent severe unexplained hypoglycaemia Known suspect drug/alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Growth hormone</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>cortisol</keyword>
</DOC>